

EDITORIAL

CHOICE OF DIURETICS FOR TREATMENT OF ESSENTIAL HYPERTENSION

Thiazide diuretics are recommended as first-line therapy for the treatment of essential hypertension by all the major guidelines¹⁻³ including those of the Southern African Hypertension Society.⁴ This is based on the fact that diureticbased therapy compared with placebo has proven benefits in reducing cardiovascular endpoints in large prospective randomised trials.56 Antihypertensive therapy does not normalise coronary heart disease (CHD) morbidity and mortality in hypertensive patients. Thiazide diuretics may cause hypokalaemia, hyperuricaemia, glucose intolerance, and a worsening lipid profile, all of which are risk factors for CHD and may mitigate against the benefits of blood pressure lowering. This led to the hypothesis that the newer drugs, which are either metabolically neutral (angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers) or beneficial (a-blockers), would be superior to diuretics in the prevention of CHD in hypertensive patients. Secondly, a more metabolically neutral diuretic would also be an alternative solution.

Regarding the first issue, several major outcome studies have been completed which test this hypothesis. In the CAPPP,7 NORDIL⁸ and STOP-2⁹ trials conventional therapy (diuretics and β -blockers) was compared with the newer therapies (calcium channel blockers and/or ACE inhibitors). None of these trials demonstrated any differences in the primary outcomes of cardiovascular morbidity and death. The INSIGHT trial¹⁰ compared the fixed combination of hydrochlorothiazide and amiloride with nifedipine GITS, and showed no differences in the primary endpoints. In the ALLHAT study" chlorthalidone was compared with amlodipine, doxazosin or lisinopril on the primary endpoint of fatal and non-fatal CHD. The doxazosin arm was terminated early by the Data and Safety Committee because doxazosin was associated with a doubling of the risk of cardiac failure. As a result of these studies most guidelines have maintained that diuretics and/or β -blockers should be used as first-line therapy for uncomplicated essential hypertension.

Regarding the second issue, indapamide immediate release (IR), a thiazide-related sulphonamide diuretic, was developed in the early 1970s, and was found to be an effective antihypertensive at a daily dose of 2.5 mg. Initial studies showed it to have fewer adverse effects on lipid and carbohydrate metabolism, but like the thiazides it has been associated with hyperuricaemia and hypokalaemia.^{12,13} However, all these initial studies tended to compare indapamide with high-dose thiazides.^{13,14} Since the development of indapamide clinical practice has changed and thiazides are seldom used in doses exceeding 25 mg daily. In the recent TOMHS study¹⁵ chlorthalidone 15 mg daily was as effective as the other major classes of antihypertensive drugs in lowering blood pressure, but was not associated with adverse effects on lipids or glucose. A recent study found no differences between hydrochlorothiazide 25 mg and indapamide IR 2.5 mg.¹⁶

No major outcome study has compared indapamide with hydrochlorothiazide or other classes of drug. However, in the PROGRESS study,¹⁷ a large randomised double-blind study comparing perindopril with and without indapamide versus placebo in the secondary prevention of stroke, indapamide IR 2.5 mg was used as add-on therapy to perindopril for blood pressure control, and was found to be a very important factor in the 28% reduction of secondary stroke reported in this study.

In this edition of the *Journal* Radevski *et al.* report that indapamide IR 2.5 mg was superior to hydrochlorothiazide 12.5 mg in lowering blood pressure in black patients with essential hypertension over a 30-month period.¹⁸ This is a wellconducted study, and its strength is that the blood pressure findings were supported by 24-hour ambulatory blood pressure monitoring. However, the findings must be read with caution as it is a small study involving only 42 patients. Larger numbers of patients are needed to show equivalence or superiority of antihypertensive drugs to avoid the inherent pitfalls of the individual variability of blood pressure response.

The introduction of the indapamide sustained release (SR) 1.5 mg may be an important advance. The SR preparation allows the lowest possible dose to be used, avoiding the adverse metabolic problems while effectively lowering blood pressure throughout the 24-hour period.¹⁹⁻²¹ Again no large outcome studies have been conducted to determine benefits on cardiovascular morbidity and mortality, but there is evidence of benefit on a surrogate marker of cardiovascular disease. In the LIVE study²² indapamide SR 1.5 mg was shown to be more effective in reducing left ventricular hypertrophy in hypertensive patients than the comparator enalapril over a 12-month period.

In summary, diuretics are first-line therapy in the treatment of uncomplicated essential hypertension. In doses used in current clinical practice thiazides and indapamide IR probably have similar metabolic and blood pressure-lowering effects, but in black hypertensives with poorly controlled blood pressure a switch from a thiazide to indapamide may be a reasonable change based on the report by Radevski *et al.* Indapamide SR may offer benefits because of its ultra-low-dose and SR formulation, but this remains to be proved by large outcome

Editorial



studies. Currently choice of diuretics should be determined largely by cost.


Brian Rayner

Division of Hypertension Groote Schuur Hospital and University of Cape Town

- Ramsay LE, Williams B, Johnston GD, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
- Guidelines Subcommittee. 1999 World Health Organisation-International Society of Hypertension. J Hypertens 1999; 17: 151-183.
- Sixth Report of the Joint National Committee of Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
- Southern African Hypertension Society Executive Committee 2000. Hypertension Clinical Guideline 2000. S Afr Med J 2001; 91: 163-171.
- SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991; 265: 3255-3264.
- Collins R, MacMahon R. Blood pressure, antihypertensive drug treatment and risks of stroke and coronary heart disease. Br Med Bull 1994; 50: 272-298.
- Hansson L, Lindholm L. Niskanen L, et al. Effects of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet* 1999; 353: 611-616.
- Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of the effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.
- Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with hypertension-2 study. Lancet 1999; 354: 1751-1756.
- Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-372.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 183: 1967-1975.
- Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. *Am J Cardiol* 1996; 77 (6): 12b-16b.
- Beling S, Vukovich RA, Neiss ES. Zisblatt M, Webb E, Losi M. Long-term experience with indapamide. Am Heart J 1983; 106: 258-262.
- 14. Plante GE, Dessurault DL. Hypertension in elderly patients. A comparative study between indapamide and hydrochlorothiazide. *Am J Med* 1988; 84(1B): 98-103.
- Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270: 712-724.
- Spence JD, Huff M, Barnett PA. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. *Can J Clin Pharmacol* 2000; 7 (1): 32-37.
- Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressurelowering regimen among 6 105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; 358: 1033-1041.
- Radevski IV, Valtchanova ZP, Candy GP, Wald AM, Ngcezula T, Sareli P. Comparison of indapamide and low-dose hydrochlorothiazide monotherapy in black patients with mild to moderate hypertension. S Afr Med J 2002; 92:
- Ambrosioni E, Safar M, Degaute J-P, et al. European Study Group. Low-dose antihypertensive therapy with 1.5 mg sustained release indapamide: results of randomised double-blind controlled studies. J Hypertens 1998; 16: 1677-1684.
- Bulpitt CJ, Emeriau JP, Knauf H, et al., Equivalence of antihypertensive effect of indapamide sustained-release (SR), hydrochlorothiazide 25 mg and amlodipine 5 mg in hypertension. J Hypertens 1997; 15 (S14): S 130.
- Mallion J-M, Asmar R, Boutelant S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide, 1.5 mg sustained release: results of two randomised double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32: 673-678.
- Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465-1475.

ABC of Hypertension 4/e

Editors: G Y H Lip, Eoin O'Brien & G Beevers This edition has been updated with colour illustrations, including new chapters on diabetes, risk stratification and pathophysiology. It traces the development of blood pressure measurement and highlights the increasing dependence on ambulatory and self-measurement of blood pressure. The age of automation is changing the approach to measurement and this is clearly demonstrated in this edition.



Nov 2000, pback, 120 pp, 297 x 212 mm, BMJ, R322

Blood Pressure

Measurement CD-ROM

Editor: James C. Petrie

This CD-ROM provides instructions on all forms of blood pressure measurement, discussing the pitfalls and problems of different techniques. It includes ambulatory blood pressure measurement, and is fully interactive, with assessment tutorials and self testing sequences of falling mercury.




1999, BMJ, R380

Recommendations on Blood

Pressure Measurement 2/e

M Dillon, W Littler, F Mee, E O'Brien, J Petrie & M de Swiet

Based on the revised British Hypertension Society recommendations on blood pressure management, this text provides the information health professionals need to know, from types of equipment available, blood pressure measurement in special circumstances, to hazards such as "white coat hypertension" and misleading readings.



525

1997, pback, 32 pp, 216 x 138 mm, BMJ, R115

Evidence Based Hypertension

Edited by Cindy Mulrow

This is a practice-oriented textbook for primary care clinicians on managing hypertension. The book summarizes all available research evidence that clinicians need to care for hypertensive patients. It also interprets the data to make it meaningful and useful and advises readers about the quality and quantity of the evidence supporting the findings. Some of the main topics addressed in this book include taking accurate blood pressure measurements, determining the effectiveness of various blood pressure treatments, controlling difficult to control blood pressure, and treating hypertensive patients with other comorbid conditions.

2001, paperback, 256 pp, 216 X 138 mm, BMJ, R485

ORDERS: The South African Medical Association, Private Bag X1, Pinelands 7430. Tel (021) 530-6527. Fax (021) 531-4126. E-mail: fpalm@samedical.org Please allow 3-4 weeks for delivery. Prices subject to foreign exchange fluctuations.